Dicyclohexyl-[2-[2,4,6-tris(2-methylpropyl)phenyl]phenyl]phosphane

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Dicyclohexyl-[2-[2,4,6-tris(2-methylpropyl)phenyl]phenyl]phosphane
• 英文别名: dicyclohexyl-[2-[2,4,6-tris(2-methylpropyl)phenyl]phenyl]phosphane
• 化学式: C₃₆H₅₅P
• 分子量: 518.8
• InChiKey: CQSLLEFUHIZMKJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  11.5
• 重原子数：
  37
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

文献信息

• [EN] SILICON-BASED CROSS COUPLING AGENTS AND METHODS OF THEIR USE<br/>[FR] AGENTS DE COUPLAGE CROISÉ À BASE DE SILICIUM ET LEURS PROCÉDÉS D'UTILISATION
  申请人：UNIV PENNSYLVANIA

  公开号：WO2016011231A1

  公开（公告）日：2016-01-21

  Compositions and methods using silicon-based cross-coupling agents in the formation of carbon-carbon and carbon-nitrogen bonds are described.

  描述了在形成碳-碳和碳-氮键过程中使用基于硅的交叉偶联试剂的组合物和方法。
• [EN] NOVEL DIHYDROPYRIDOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS<br/>[FR] NOUVELLES DIHYDROPYRIDOISOQUINOLINONES ET LEURS COMPOSITIONS PHARMACEUTIQUES POUR LE TRAITEMENT DE TROUBLES INFLAMMATOIRES
  申请人：GALAPAGOS NV

  公开号：WO2016169911A1

  公开（公告）日：2016-10-27

  A compound according to Formula (I): wherein R1, LA, CyA, RA, R2, R3, and R4 are as described herein. The present invention relates to novel compounds according to Formula I that antagonize GPR84, a G-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions, pain, neuroinflammatory conditions, neurodegenerative conditions, infectious diseases, autoimmune diseases, endocrine and/or metabolic diseases, cardiovascular diseases, leukemia, and/or diseases involving impairment of immune cell functions by administering a compound of the invention.

  根据公式（I）的化合物：其中R1、LA、CyA、RA、R2、R3和R4如本文所述。本发明涉及根据公式I的新化合物，这些化合物拮抗GPR84，GPR84是涉及炎症状况的G蛋白偶联受体，以及制备这些新化合物的方法，包括这些化合物的药物组合物，以及通过给予本发明的化合物预防和/或治疗炎症状况、疼痛、神经炎症状况、神经退行性疾病、传染病、自身免疫疾病、内分泌和/或代谢疾病、心血管疾病、白血病和/或通过给予本发明的化合物导致免疫细胞功能受损的疾病的方法。
• POLYMER ELECTROLYTE COMPOSITION, AND POLYMER ELECTROLYTE MEMBRANE, MEMBRANE ELECTRODE ASSEMBLY AND SOLID POLYMER FUEL CELL EACH USING SAME
  申请人：TORAY INDUSTRIES, INC.

  公开号：US20140377686A1

  公开（公告）日：2014-12-25

  Provided are: a practically excellent polymer electrolyte composition having excellent chemical stability of being resistant to strong oxidizing atmosphere during operation of fuel cell, and achieving excellent proton conductivity under low-humidification conditions, excellent mechanical strength and physical durability; a polymer electrolyte membrane, a membrane electrode assembly, and a polymer electrolyte fuel cell each using the same. The polymer electrolyte composition of the present invention comprises at least an ionic group-containing polymer (A) and a phosphorus-containing additive (B), the phosphorus-containing additive (B) being at least one of a phosphine compound and a phosphinite compound. The polymer electrolyte membrane, the membrane electrode assembly, and the polymer electrolyte fuel cell of the present invention are structured by the polymer electrolyte composition.

  提供了一种具有优异化学稳定性，在燃料电池操作期间对强氧化气氛具有抗性，并在低加湿条件下实现优异的质子传导性、优异的机械强度和物理耐久性的实用优良聚合物电解质组成物；以及使用相同组成物的聚合物电解质膜、膜电极组件和聚合物电解质燃料电池。本发明的聚合物电解质组成物包括至少一种离子基团含有的聚合物（A）和一种含磷添加剂（B），该含磷添加剂（B）至少为膦化合物和膦酸酯化合物中的一种。本发明的聚合物电解质膜、膜电极组件和聚合物电解质燃料电池由聚合物电解质组成物构成。
• SILICON-BASED CROSS COUPLING AGENTS AND METHODS OF THEIR USE
  申请人：The Trustees of The University of Pennsylvania

  公开号：US20150152216A1

  公开（公告）日：2015-06-04

  Compositions and methods using silicon-based cross-coupling agents in the formation of carbon-carbon and carbon-nitrogen bonds are described.

  本文描述了使用基于硅的交叉偶联剂在形成碳-碳和碳-氮键中的组合物和方法。
• VOLTAGE-GATED SODIUM CHANNEL BLOCKERS
  申请人：Boehm Jeffrey Charles

  公开号：US20140121213A1

  公开（公告）日：2014-05-01

  In general, the present invention relates to uses of voltage-gated sodium channel blocker compounds, which include corresponding precursors, intermediates, monomers and dimers, corresponding pharmaceutical compositions, compound preparation and treatment methods for respiratory and respiratory tract diseases. In particular, the present invention also relates to methods and uses for treatment of respiratory or respiratory tract diseases, which comprises administering to a subject in need thereof an effective amount of a compound of the present invention.

  一般而言，本发明涉及使用电压门控钠通道阻滞剂化合物，包括相应的前体、中间体、单体和二聚体，相应的制药组合物，化合物制备和治疗呼吸系统和呼吸道疾病的方法。特别是，本发明还涉及治疗呼吸系统或呼吸道疾病的方法和用途，包括向需要的受试者投与本发明化合物的有效量。